- Kolosis bone grafts available in over 270 hospitals and surgical facilities in 46 states
- Grafts utilized in approximately 6000 fusion procedures during the year
- Expanded national footprint through ~100 independent distributors
- Successful launch of Kore Fiber with rapid market adoption and positive early clinical performance. Kore added to over 30 health system and GPO contracts
Kolosis BIO, LLC (Kolosis), a pure-play orthobiologics company and an exclusive partner to MTF Biologics, announced today its 2021 results and 2022 expectations.
2021 saw strong revenue growth primarily driven by the launch of Kore Fiber and by the continued strong performance of the Prime HD DBM tissue-form. Kolosis anticipates doubling its revenue in 2022 as it grows its direct and indirect sales force, expands contractual access for its bone graft portfolio, and provides additional scientific evidence for its technologies.
“We couldn’t be more pleased with the launch of Kore Fiber and the interest in the technology we are seeing from clinicians and sales partners alike,” said Collin Begley, CEO. “Delivering high quality MTF grafts to over 6000 patients during the year is a humbling accomplishment for our team. Looking towards 2022 and beyond, our salesforce expansion trajectory, scientific initiatives, and initial clinical outcomes give us a pathway to deliver continued robust growth.”
Kolosis President, Keegan Begley, added, “Our value proposition in the market is extremely compelling with best-in-class aseptically processed technologies from MTF and rapidly expanding contract access for our bone graft portfolio. I’m pleased with our performance and that we’re delivering a level of responsiveness to our customers that is simply impossible for our big company competitors to match.”